Supernus Pharmaceuticals, Inc.

NasdaqGM:SUPN Stock Report

Market Cap: US$1.7b

Supernus Pharmaceuticals Past Earnings Performance

Past criteria checks 0/6

Supernus Pharmaceuticals's earnings have been declining at an average annual rate of -25%, while the Pharmaceuticals industry saw earnings growing at 1% annually. Revenues have been growing at an average rate of 11.4% per year. Supernus Pharmaceuticals's return on equity is 0.1%, and it has net margins of 0.2%.

Key information

-25.0%

Earnings growth rate

-25.6%

EPS growth rate

Pharmaceuticals Industry Growth6.0%
Revenue growth rate11.4%
Return on equity0.1%
Net Margin0.2%
Next Earnings Update08 May 2024

Recent past performance updates

Recent updates

Subdued Growth No Barrier To Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Price

Apr 24
Subdued Growth No Barrier To Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Price

Supernus Pharmaceuticals: Moving Through An 'Inflection Year'

Mar 04

We Think Supernus Pharmaceuticals (NASDAQ:SUPN) Can Stay On Top Of Its Debt

May 10
We Think Supernus Pharmaceuticals (NASDAQ:SUPN) Can Stay On Top Of Its Debt

Does Supernus Pharmaceuticals (NASDAQ:SUPN) Have A Healthy Balance Sheet?

Feb 03
Does Supernus Pharmaceuticals (NASDAQ:SUPN) Have A Healthy Balance Sheet?

These 4 Measures Indicate That Supernus Pharmaceuticals (NASDAQ:SUPN) Is Using Debt Reasonably Well

Oct 19
These 4 Measures Indicate That Supernus Pharmaceuticals (NASDAQ:SUPN) Is Using Debt Reasonably Well

Supernus stock falls 12.6% after FDA declines to approve Parkinson’s disease treatment

Oct 10

Supernus Pharmaceuticals: Deep Expertise In CNS, Eyes On Qelbree Launch And Parkinson Portfolio

Aug 19

Supernus Pharmaceuticals' (NASDAQ:SUPN) Soft Earnings Are Actually Better Than They Appear

Aug 16
Supernus Pharmaceuticals' (NASDAQ:SUPN) Soft Earnings Are Actually Better Than They Appear

Supernus: A Work In Progress

Jul 29

Supernus: New Beginnings

Mar 28

Brokers Are Upgrading Their Views On Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) With These New Forecasts

Dec 02
Brokers Are Upgrading Their Views On Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) With These New Forecasts

Is Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Trading At A 34% Discount?

Nov 30
Is Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Trading At A 34% Discount?

Is Supernus Pharmaceuticals (NASDAQ:SUPN) Using Too Much Debt?

Oct 19
Is Supernus Pharmaceuticals (NASDAQ:SUPN) Using Too Much Debt?

Is Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Trading At A 49% Discount?

Aug 31
Is Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Trading At A 49% Discount?

Supernus: Well Prepared For Upcoming Challenges

Aug 26

Supernus Pharmaceuticals (NASDAQ:SUPN) Seems To Use Debt Rather Sparingly

Jul 05
Supernus Pharmaceuticals (NASDAQ:SUPN) Seems To Use Debt Rather Sparingly

Revenue & Expenses Breakdown
Beta

How Supernus Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqGM:SUPN Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 23608133692
30 Sep 236112632986
30 Jun 236344335983
31 Mar 236685237275
31 Dec 226676137775
30 Sep 226593840578
30 Jun 226305736578
31 Mar 226017333477
31 Dec 215805330590
30 Sep 215648225187
30 Jun 2157110023485
31 Mar 2155611121291
31 Dec 2052012720176
30 Sep 2047712917778
30 Jun 2042411816278
31 Mar 2040211615273
31 Dec 1939311315369
30 Sep 1940810616165
30 Jun 1940910516269
31 Mar 1940410316472
31 Dec 1840911115589
30 Sep 183819915276
30 Jun 183598715268
31 Mar 183357314759
31 Dec 173025713850
30 Sep 172765813347
30 Jun 1725310411842
31 Mar 172289710942
31 Dec 162159110643
30 Sep 161968410139
30 Jun 16179269840
31 Mar 16163189536
31 Dec 15147148929
30 Sep 15135118425
30 Jun 1511857821
31 Mar 1511257419
31 Dec 1493-117320
30 Sep 1472-377019
30 Jun 1450-596718
31 Mar 1421-896017
31 Dec 1312-925617
30 Sep 133-834917
30 Jun 132-733922

Quality Earnings: SUPN has a large one-off loss of $18.7M impacting its last 12 months of financial results to 31st December, 2023.

Growing Profit Margin: SUPN's current net profit margins (0.2%) are lower than last year (9.1%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: SUPN's earnings have declined by 25% per year over the past 5 years.

Accelerating Growth: SUPN's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: SUPN had negative earnings growth (-97.8%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-13.2%).


Return on Equity

High ROE: SUPN's Return on Equity (0.1%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.